When The Longship Everyone Abandoned Sets Sail

Let me tell you about the worst day I’ve had watching a biotech stock in years. August 19, 2025. Viking Therapeutics (VKTX) reported its oral VK2735 data, and the stock dropped 40% before I could finish my morning coffee.

My phone exploded with panicked messages from people who’d clearly only read the headlines. “High discontinuation rates!” “It’s over!”

I pulled up the actual trial data and started laughing. Not because losing 40% in a day is funny, but because I’ve seen this movie before. The crowd was stampeding toward the exit over a titration problem while completely missing what just happened.

Viking proved their molecule works brilliantly, showed nearly 15% weight loss at just 13 weeks, and handed the market a roadmap for exactly how to fix the tolerability issues in Phase 3.

So what did people miss before they started dumping shares? Ninety-eight percent of the adverse events were mild or moderate.

The gastrointestinal complaints peaked early and subsided over time. The discontinuations tracked directly with how fast they ramped up the dose.

Everything that spooked the market was a function of trial design, not some fundamental flaw in the drug itself. This was textbook “escalated too aggressively, slow it down next time” territory.

But that’s not the most interesting part for me. Viking is running both injectable and oral versions of the same molecule simultaneously. Think about the strategic brilliance of that.

You start patients on the injectable form, which already showed spectacular efficacy with up to 14.7% mean weight loss and a safety profile so clean it could pass a white glove inspection.

Then you transition them to the oral form for maintenance. Same molecule, so the body’s already adapted.

The tolerability issues that caused all the hand-wringing? They largely disappear when you’re using oral as a maintenance agent after the injectable does the heavy lifting.

I had a conversation a few months back with a friend who spent two decades developing drugs at one of the major pharmas. He walked me through what really separates winners from losers in the obesity space. It’s not just efficacy numbers, it’s real-world usability and patient adherence.

Viking’s injectable showed something in Phase 2 that made even the bulls sit up straight. Seven weeks after the last dose, patients still maintained over 90% of their weight loss.

That tissue half-life opens the door to monthly dosing instead of weekly injections, which transforms the entire patient experience. Weekly is manageable. Monthly is “I barely think about this” territory.

Now, let’s talk about the CordenPharma manufacturing deal, because this tells you everything about how management is thinking. They locked-in capacity for over one billion oral tablets annually and 100 million injectable units.

You don’t commit that kind of industrial infrastructure on a whim. You do it because you’re either supremely confident you’re going all the way independently, or you’re building the exact kind of credible alternative that forces Big Pharma to pay premium prices in acquisition talks. The best negotiating position is not needing the deal.

The valuation math is almost comically straightforward once you strip away the noise. The GLP-1 market is heading toward $100 billion globally by decade’s end.

Viking doesn’t need to dethrone Novo Nordisk (NVO) or Eli Lilly (LLY). They just need to be the credible third player in a massive market.

Even a modest 5% share implies $5 billion in revenue. Clinical-stage companies with de-risked Phase 2 data in validated markets routinely get bought out at three to five times revenue multiples. Viking’s current market cap is $3 billion. You do the math.

What the market is pricing in right now is roughly coin-flip odds that everything fails. The injectable crashes in Phase 3, the oral never gets approved, and VK2809 for MASH goes nowhere. Is that probable when you actually look at the data? Not even close.

The injectable has already demonstrated potentially best-in-class efficacy with pristine safety data. The oral proved the mechanism works, and the discontinuation issues are fixable with a better trial design.

So here’s where they stand: Viking has roughly $800 million in cash, burns around $60 million to $70 million per quarter even with two Phase 3 trials running, and has about four years of runway. That optionality is worth its weight in gold. They can partner selectively, negotiate from strength, or march straight through to approval with the manufacturing backbone already locked in.

Should you mortgage the house and back up the truck? Absolutely not. This is biotech, and clinical trials can fail for reasons nobody sees coming.

But should you be nibbling here, building a position slowly while everyone else is still traumatized from August? Yes, because the risk-reward is skewed heavily in your favor when the market is pricing in failure odds that don’t remotely match the clinical reality.

The key is having the right temperament. If you can’t watch a position drop 40% in a day and still calmly evaluate whether the underlying thesis actually changed, biotech isn’t your game.

If you can separate market hysteria from fundamental value, though, then Viking at $3 billion is exactly the kind of setup where fear created a genuine mispricing. Start small, add on weakness, and give it time.